Galenica to enter the diagnostics business by acquiring Labor Team
Werte in diesem Artikel
Galenica AG / Key word(s): Mergers & Acquisitions Werbung Werbung Press release
Galenica Ltd. is acquiring Diagnostics Group GmbH (hereinafter the Labor Team Group) and will enter the diagnostics business. The planned acquisition of Switzerland’s fourth-largest medical laboratory will give Galenica access to a leading diagnostic service provider with a strong market position. This enables Galenica to continue along its path of growth and to strengthen its healthcare network and value chain with an additional strategic business area. The transaction requires the approval of the Swiss Competition Commission (COMCO). Werbung Werbung “Labor Team is a perfect fit for our strategic focus and our goal further connecting the healthcare sector. The business activities of Labor Team and Galenica are an ideal match, and the two companies share highly compatible corporate cultures. Both companies want to drive forward healthcare innovations,” says Galenica CEO Marc Werner. “By joining the Galenica network, we can further expand our leading position and make our broad-ranging offering even more widely available throughout Switzerland. In addition, Galenica’s corporate culture offers the best conditions for innovations in the field of diagnostics,” says Dr med. Alain M. Cahen, CEO of Labor Team. Stronger networking and innovation in Swiss healthcareWerbung Werbung Labor Team offers a comprehensive range of services from laboratory medicine and pathology to personalised special diagnostics. The company operates the largest central laboratory in Switzerland in Goldach, St. Gallen, which is integrated into an efficient logistics network and is complemented by several specialist laboratories throughout Switzerland. This means that samples can be delivered to the central laboratory for analysis within 30 minutes to a maximum of five hours from anywhere within Switzerland. Within the physicians’ market, Labor Team’s main customer segment, Galenica already holds a leading position in the wholesale pharmaceuticals market with a market share of around 31%. The acquisition is an ideal strategic addition to the Galenica network. In addition to the existing offerings in the area of drugs and products for the physicians’ market, it will also be possible to offer innovative laboratory services as a single provider. Labor Team will also gain access to potential new customers. In the long term, Galenica plans to work with Labor Team to develop an innovative range of selected diagnostic laboratory services for end users and patients within the scope of the possibilities afforded to pharmacies by the regulatory frameworks in place. This will further strengthen healthcare for patients in Switzerland. Continuity in managementIn future Labor Team is set to be managed as an independent “Galenica Diagnostics” business unit and to be reported in the “Products & Care” segment. The current management will continue to bear operational responsibility and will continue the success story of Labor Team and its more than 330 employees. The main site in Goldach and all subsidiaries will remain unchanged. Key financial figures and planned closingLabor Team has a market share of around 8% in Switzerland’s continuously growing market for private laboratories. In particular, Growth drivers include demographic change, higher demand for healthcare services and an increase in specialised outpatient diagnostics. Combined net sales of Labor Team Group in 2024 amounted to CHF 114 million. The laboratory market is expected to be affected by further regulatory changes relating to tariffs in the coming years, which is likely to drive market consolidation. In acquiring Labor Team with its highly automated central laboratory and efficient logistics, Galenica considers itself well positioned to rise to these challenges. Financing will be executed by means of bridge debt financing in the short term. The parties have agreed not to disclose the sale price. The transaction will be completed following COMCO approval, which is expected in the second half of 2025. Upcoming dates
For further information, please contact:
Welcome to the Galenica network! Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALE, security number 36,067,446). Find out more about Galenica at www.galenica.com. About labor team w ag End of Inside Information |
Language: | English |
Company: | Galenica AG |
Untermattweg 8 | |
3027 Bern | |
Switzerland | |
Phone: | +41 058 852 81 11 |
E-mail: | info@galenica.com |
Internet: | https://www.galenica.com |
ISIN: | CH0360674466 |
Listed: | SIX Swiss Exchange |
EQS News ID: | 2163362 |
End of Announcement | EQS News Service |
|
2163362 02-Jul-2025 CET/CEST
Ausgewählte Hebelprodukte auf Galenica
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Galenica
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu Galenica AG
Analysen zu Galenica AG
Datum | Rating | Analyst | |
---|---|---|---|
11.02.2013 | Galenica verkaufen | Vontobel Research | |
18.01.2013 | Galenica verkaufen | Vontobel Research | |
03.12.2012 | Galenica reduce | Vontobel Research | |
15.08.2012 | Galenica reduce | Vontobel Research | |
14.08.2012 | Galenica neutral | Sarasin Research |
Datum | Rating | Analyst | |
---|---|---|---|
01.12.2010 | Galenica buy | Vontobel Research | |
17.09.2010 | Galenica buy | Vontobel Research | |
02.09.2010 | Galenica buy | Vontobel Research | |
27.08.2010 | Galenica buy | Vontobel Research | |
18.08.2010 | Galenica buy | Vontobel Research |
Datum | Rating | Analyst | |
---|---|---|---|
14.08.2012 | Galenica neutral | Sarasin Research | |
10.07.2012 | Galenica neutral | Sarasin Research | |
09.07.2012 | Galenica hold | Vontobel Research | |
27.06.2012 | Galenica hold | Vontobel Research | |
13.03.2012 | Galenica neutral | Sarasin Research |
Datum | Rating | Analyst | |
---|---|---|---|
11.02.2013 | Galenica verkaufen | Vontobel Research | |
18.01.2013 | Galenica verkaufen | Vontobel Research | |
03.12.2012 | Galenica reduce | Vontobel Research | |
15.08.2012 | Galenica reduce | Vontobel Research | |
26.07.2012 | Galenica reduce | Vontobel Research |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Galenica AG nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen